Organization Sep 29, 2022 California Governor Signs Cancer Care Equity Act Into Law Sep 27, 2022 Thermo Fisher Gets FDA OK for CDx Test to Guide Use of Lilly Drug in Lung, Thyroid Cancers Sep 27, 2022 Tavros Therapeutics Raises $7.5M to Advance Biomarker-Directed Cancer Drug Discovery Platform Sep 26, 2022 WEHI Launches Project to Improve Genomic Data Interpretation, Precision Cancer Care in Australia Sep 23, 2022 NICE Recommends Pfizer's Ibrance Combination for HER2-Negative Breast Cancer Sep 21, 2022 Sophia Genetics Partners With MSK on Clinical Decision Support, Boundless Bio on ecDNA Detection Sep 20, 2022 Transcriptomics Plus 'Immune Tolerance' of Normal Tissue Shows Promise in Lung Cancer Prognosis Premium Sep 20, 2022 Verismo Therapeutics to Begin Phase I Trial of Autologous Cell Therapy SynKIR-110 Sep 19, 2022 EMA's CHMP Recommends Gilead's Yescarta for Second-Line Lymphoma Sep 16, 2022 BMS Combo Immunotherapy Opdualag Approved in Europe for Biomarker-Defined Melanoma Patients Sep 14, 2022 Biomarker Test Access for Precision Oncology Varies Widely in Europe, ESMO Survey Finds Premium Sep 14, 2022 MD Anderson, Radiopharm Theranostics Launch Radiopharmaceuticals Joint Venture Sep 13, 2022 Combination Trials Point to New Potential Treatment Strategies in Breast Cancer Premium Sep 13, 2022 Relay Therapeutics' Selective FGFR2 Inhibitor Yields 'Remarkable' Responses in Bile Duct Cancer Premium Sep 13, 2022 ESMO Data Deepens Understanding of KRAS Inhibitor Activity in Lung, Colorectal Cancer Premium Sep 13, 2022 Imaging Agent May Have Potential as Noninvasive Test to Predict PARP Inhibitor Response Sep 13, 2022 Nearly all dMMR Colon Cancer Patients Respond in Trial of Neoadjuvant Opdivo-Yervoy Premium Sep 12, 2022 ESMO Data Sharpens View of How Grail, Exact Sciences Multi-Cancer Early Detection Tests Perform Premium Sep 11, 2022 Repeat Biomarker Testing Informs Next Steps for Treatment-Resistant EGFR-Mutant NSCLC Patients Premium Sep 11, 2022 Selective Estrogen Receptor Degraders, Modulators Show Promise in ESR1-Mutant Breast Cancer Premium Load More Breaking News FDA Approves Taiho Oncology's Lytgobi for FGFR2-Rearranged Bile Duct Cancer Gladstone Institute Joins With Parker Institute on New Center to Study CRISPR-Based Cell Therapies Meliora Therapeutics Raises $11M in Seed Financing In Brief This Week:Â Verismo Therapeutics, Fore Biotherapeutics, Merck, Caris Life Sciences Tumor-Only Sequencing Found to Overestimate Mutational Burden in Non-European Patients Atara Biotherapeutics to Net $30M From Pierre Fabre for European Tab-Cel Approval
